VANDA Pharmaceuticals - Investor Relations - IR Home

Investor Relations

Press Releases

Print Page Print Page
<< Back
Vanda Pharmaceuticals to Announce Second Quarter 2015 Financial Results on July 29, 2015
Conference Call and Webcast to Follow

WASHINGTON, July 9, 2015 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the second quarter of 2015 on Wednesday, July 29, 2015, after the market closes.

The Company will host a conference call at 4:30 PM ET on Wednesday, July 29, 2015, during which Vanda management will discuss the second quarter 2015 financial results and other corporate activities. To participate in the conference call, please dial 1-800-708-4539 (domestic) or 1-847-619-6396 (international) and use passcode 40193344.

The conference call will be broadcast simultaneously and archived on the Company's website, www.vandapharma.com.  Investors should go to the website at least 15 minutes early to register, download, and install any necessary audio software.

A replay of the call will be available on Wednesday, July 29, 2015, beginning at 7:00 PM ET and will be accessible until Wednesday, August 5, 2015, at 11:59 PM ET.  The replay call-in number is 1-888-843-7419 for domestic callers and 1-630-652-3042 for international callers.  The passcode number is 40193344.

ABOUT VANDA PHARMACEUTICALS INC.:
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders.  For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com.  

Investor Contact:
Jim Kelly
Senior Vice President & Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
jim.kelly@vandapharma.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/vanda-pharmaceuticals-to-announce-second-quarter-2015-financial-results-on-july-29-2015-300109696.html

SOURCE Vanda Pharmaceuticals Inc.

Copyright © 2005-2024 Vanda Pharmaceuticals Inc. |